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Fellowships: Human Embryonic Stem Cell Research
The purpose of this program announcement (PA) is to
increase the number of biomedical scientists who are
pursuing research involving human embryonic stem
cells (HESCs). The recent availability of HESCs for
federally funded research affords a unique opportunity
for investigators to use these cells to address research
questions of interest to the mission of the NIH and its
component institutes and centers. 
Although HESCs have great potential to yield
important information on the fundamental properties
of cells and disease processes, remarkably little is
known about the properties of HESCs that distinguish
them from more differentiated cells. Furthermore, very
few scientists have had the opportunity to be trained in
their use, or to explore the questions that can be
addressed to advantage using HESCs. As a result, only
a few postdoctoral fellows and established investigators
are currently engaged in HESC research, and more
investigators must be trained to accelerate the pace of
HESC research. Indeed, the NIH Stem Cell Task
Force has identiﬁed the paucity of skilled researchers
and lack of training environments for career enrich-
ment as an important limiting step in the advancement
of HESC research.
This PA specifically aims to encourage applica-
tions for F32 individual postdoctoral fellowships from
promising candidates with the potential to become
productive, independent investigators in HESC-related
research. It also aims to encourage applications for F33
senior fellowships from experienced scientists who wish
to make major changes in the direction of their
research or who wish to broaden their scientiﬁc back-
ground by acquiring new capabilities in HESC
research. Only approved HESC lines listed on the
NIH Human Embryonic Stem Cell Registry
(http://stemcells.nih.gov/registry/) may be used for
research training activities. The application must pro-
vide the registry identifying numbers of the HESC
lines to be used.
The goal of this fellowship program in HESC
research is to train highly skilled research scientists to
pursue research problems on the basic characteristics of
HESCs and their applications to the study of disease. It
is expected that these individuals will acquire expertise
in the growth and maintenance of HESC that will
enable them to pursue research that includes: 1) estab-
lishment of HESCs as model systems to explore the
fundamental properties of HESCs and their more dif-
ferentiated progeny; 2) characterization of the molecu-
lar events in the differentiation of speciﬁc cell types and
tissue lineages; 3) establishment of HESCs as model
systems for the study of specific diseases; 4) use of
HESCs as a primary cell type in drug discovery; and 5)
exploration of the therapeutic potential of HESCs in
regenerative medicine.
This funding opportunity will use the Kirschstein-
NRSA F32 and F33 individual award mechanisms. As
an applicant, you will be solely responsible for plan-
ning, directing, and executing the proposed project.
The number of awards will depend on the quality of
applications and funds available.
Applications must be prepared using the PHS
416-1 forms (rev. 6/2002). The PHS 416-1 is available
at http://grants.nih.gov/grants/forms.htm in an inter-
active format. For further assistance contact
GrantsInfo, 301-435-0714, e-mail: GrantsInfo@
nih.gov. The complete PA is available online at
http://grants.nih.gov/grants/guide/pa-files/
PA-05-013.html.
Contact: Marion M. Zatz, Division of Genetics
and Developmental Biology, NIGMS, Bldg 45, Rm
2AS.25, 45 Center Dr MSC-6200, Bethesda, MD
20892-6200 USA, 301-594-0943, fax: 301-480-2228,
e-mail: zatzm@nigms.nih.gov; Ellen M. Werner,
Division of Blood Diseases and Resources, NHLBI,
6701 Rockledge Dr, MSC 7950, Bethesda, MD
20892-7950 USA, 301-435-0061, e-mail: wernere@
mail.nih.gov; Steven L. Klein, Developmental Biology,
Genetics & Teratology Branch, NICHD, 6100
Executive Blvd, Rm 4B01, Rockville, MD 20852
USA, 301-496-5541, e-mail: sk56d@nih.gov; Daniel
A. Sklare, Division of Scientiﬁc Programs, NIDCD,
Bldg 31, Rm 400C, 6120 Executive Blvd, MSC-7180,
Bethesda, MD 20892-7180 USA, 301-496-1804, e-
mail: sklared@nidcd.nih.gov; James Hyde, Division of
Diabetes, Endocrinology, and Metabolic Diseases,
NIDDK, 6707 Democracy Blvd, Rm 609, MSC
5460, Bethesda, MD 20892-5460 USA, 301-594-
7692, e-mail: jh486z@nih.gov; Judith Podskalny,
Division of Digestive Diseases and Nutrition,
NIDDK, 6707 Democracy Blvd, Rm 667, MSC
5450, Bethesda, MD 20892-5450 USA, 301-594-
8876, e-mail: jp53s@nih.gov; Terry Rogers Bishop,
Division of Kidney, Urologic, and Hematologic
Disorders, NIDDK, 6707 Democracy Blvd, Rm 619,
MSC 5458, Bethesda, MD 20892-5458 USA, 301-
594-7717, e-mail: tb232j@nih.gov; Carol Shreffler,
Division of Extramural Research and Training,
NIEHS, PO Box 12233, Research Triangle Park, NC
27709 USA, 919-541-1445, e-mail: shreffl1@
niehs.nih.gov Reference: PA No. PA-05-013
Scholarly Works in Biomedicine and Health 
The National Library of Medicine (NLM) awards
small grants for the preparation of book-length manu-
scripts and other scholarly works of value to U.S.
health professionals, public health ofﬁcials, biomedical
researchers, and historians of the health sciences.
Grants are awarded for major critical reviews, state-of-
the-art summaries, historical studies, and other useful
organizations of knowledge in clinical medicine, public
health, biomedical research, and the informatics/infor-
mation sciences relating to them. The scholarly work
may be prepared for publication in print or nonprint
media, or both.
Scholars in biomedical fields face competing
demands for their time, including requirements for
clinical care services, grant-related research, and
administrative duties. Scholarly work draws upon
original sources that may reside within archives,
databases, libraries, or human experts around the
world, in many different languages and formats.
The work of scholarship—discovery, thoughtful
analysis, synthesis, and lucid presentation of find-
ings from such materials—requires protected time
and support for incidental costs, including materi-
als, staff assistance, and travel. The NLM Grant for
Scholarly Works in Biomedicine and Health is
intended to help defray such expenses. NLM Grants
for Scholarly Works can be used to support several
types of scholarly projects.
Historical works include 1) scholarly works in the
history or philosophy of medicine, public health and
the life sciences, the development of medical research
and health services, bioethics, and studies on the inter-
relationship of medicine and society; and 2) scholarly
works in the history or philosophy of health informat-
ics, health information sciences, biomedical commu-
nications, and health sciences librarianship.
Critical reviews include 1) analytical and com-
prehensive critical reviews which identify the present
status of research and practice in various health-
related fields, addressing advances which have been
made, problems requiring examination, and emerg-
ing trends; and 2) scientiﬁcally signiﬁcant and impor-
tant symposium or conference proceedings related to
U.S. priorities in health care, public health, and bio-
medical research.
Research aids include 1) selected secondary tools in
the health sciences, such as biomedical guides, atlases,
handbooks, dictionaries, indices, catalogs, directories,
and other unique reference materials; and 2) English-
language translations of important foreign-language
classics or primary materials in the history of medicine.
These NLM grants are designed to support schol-
arly work on a manuscript, video, or electronic
resource that will ultimately be published by a com-
mercial or academic press or similar print or electronic
dissemination service that ensures quality and availabil-
ity of the product. Self-publishing by the author will
not normally be considered an appropriate dissemina-
tion vehicle.
These NLM grants do not support the following
types of projects: 1) production of textbooks, curricu-
lum materials or online learning modules; 2) produc-
tion of works intended for lay audiences; 3) initial
reporting of original scientiﬁc research ﬁndings, includ-
ing the initial publication of dissertation research;
4) development of coding systems, ontologies, or
vocabularies for computational use; 5) publication of
proceedings of annual meetings; 6) production of jour-
nals, reprints, other serials, or other costs of publishing
such as author page charges; 7) operation of established
databases; 8) mass digitization of existing archives or
print materials; 9) work judged to have significant
commercial viability; or 10) projects of local interest
only, or works for which access is restricted to a select
group.
Applicants should include a topic or chapter out-
line of the book or work to be produced as part of the
research plan. All applicants are required to provide
NLM with a copy of the ﬁnal published work, once it
has been issued. NLM recommends that all hardcopy
text sponsored in this program be published on acid-
free permanent paper as set forth by the American
National Standards Institute Permanence of Paper for
Publications and Documents in Libraries and Archives
(ANSI/NISO Z39.48- 1992).
This funding opportunity will use the G13 award
mechanism. As an applicant, you will be solely respon-
sible for planning, directing, and executing the pro-
posed project. An NLM Publication Grant for
Scholarly Works provides up to $50,000 in direct costs
per year for one, two, or three years. These grants are
not renewable. The NLM anticipates spending approx-
imately $1.4 million per year on new awards in this
program. Because the nature and scope of the proposed
research will vary from application to application, it is
anticipated that the size and duration of each award
will also vary. 
Non-U.S. citizens may apply for these grants;
however, priority is given to U.S. citizens. Usually,
awards are made three times per year, in December/
January, March/April, and August/September. Start
dates are usually the same as the award date. The
period of performance is one, two or three years.
This funding opportunity uses the just-in-time
budget concepts. It also uses the nonmodular budget
format described in the PHS 398 application instruc-
tions (available online at http://grants.nih.gov/grants/
funding/phs398/phs398.html). A detailed categorical
budget for the initial budget period and the entire pro-
posed period of support is to be submitted with the
application. Applications must be prepared using the
PHS 398 research grant application instructions and
forms. Applications must have a Dun and Bradstreet
(D&B) Data Universal Numbering System (DUNS)
number as the universal identiﬁer when applying for
federal grants or cooperative agreements. The D&B
number can be obtained by calling 1-866-705-5711 or
through the website at http://www.dnb.com. The
D&B number should be entered on line 11 of the face
page of PHS 398. For further assistance contact
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nih.gov. Application receipt dates are 1 June, 1
November, and 1 February. A letter of intent is not
required. 
Contact: Valerie Florance, Extramural Programs
Division, NLM, Rockledge 1, Suite 301, 6705
Rockledge Dr, Bethesda, MD 20892 USA, 301-594-
4882, fax: 301-402-2952, e-mail: floranv@
mail.nih.gov. Reference: PAR No. PAR-05-025
Metals in Medicine
The objective of this program announcement (PA) is
to encourage research that bridges the areas of inor-
ganic chemistry and medicine in continuation of PA-
01-071. The National Institute of General Medical
Science (NIGMS) is joined in this announcement by
the NIEHS and the NIH Office of Dietary
Supplements (ODS). 
The mechanisms by which organisms control
transition metal ions and the roles of these metals in
cellular regulation and signaling in health and disease
are of principal interest. The interactions of synthetic
inorganic complexes with living systems and their
components are an additional area of interest. These
areas are linked by the need to involve researchers hav-
ing a deep understanding of inorganic chemistry in
medically relevant research. Much of the work is
expected to involve collaborations including chemists,
biologists, and medical researchers. The results will be
relevant to understanding the mechanisms of metal
handling by biological systems and the basic cellular
roles underlying the nutritional requirement for essen-
tial metals. It is expected that this research will also
contribute to the identiﬁcation of new targets for drug
discovery, diagnostics, and future therapeutic
approaches involving metal complexes, although drug
development, per se, is not a focus of the program.
A higher-order problem presents itself in under-
standing how the genome-encoded components and
the other molecules are constituted in networks of
interacting molecules with particular distributions in
time and space. Advances in imaging techniques and
analytic methods are beginning to yield copious quan-
titative and spatial data on speciﬁc molecules in biolog-
ical systems. Knowledge of the network and changes in
its components over time, and the local rules by which
the individual components distribute material and
information, will substantially advance our knowledge.
Studies of metalloenzyme structure and function,
mechanisms of action, and inhibition are currently
well supported and produce results that are utilized in
the design of new diagnostic and therapeutic prod-
ucts. Additional stimulation of this area is not needed.
In contrast, work in other areas of bioinorganic chem-
istry lags behind its potential application to human
health. These areas include 1) mechanisms of metal
metabolism as well as the roles of metals in regulation
of cell function and cell–cell interaction, and 2) basic
research toward diagnostic and therapeutic applica-
tions of metal complexes and of metal chelators and
toward exploiting the unique properties of metals for
therapeutic applications. The emphasis of this
announcement is on the ions, complexes, and
organometallic compounds of the transition metals
known as lanthanides and actinides, post-transition
metals, and metalloid elements.
Metal Metabolism and Regulation. Metal metabo-
lism is emerging as an exciting area of cell biology and
a potential area for therapeutic intervention. Normal
metal metabolism appears to maintain free metal ion
concentrations at a very low level and to deliver metals
very selectively to their sites of action, while maintain-
ing tight control over their reactivity. Aberrant metal
metabolism contributes to pathological conditions
such as Menkes’ disease, Wilson’s disease, and
hemochromatosis. Intercepting normal metalation
reactions may be a way to control metalloprotein activ-
ity. Metals may also be associated with the pathology
of protein aggregates such as those formed by prions
and in Alzheimer’s disease. Metals have also emerged
as important sensors and transducers of information
with roles in regulation and neurotransmission.
Areas of interest include 1) improved metal ion
sensors to study cellular metal ion concentrations and
localization; 2) reagents suitable to manipulate those
concentrations; 3) identiﬁcation and characterization
of the macromolecular players and vesicular compart-
ments involved in metal ion homeostasis and metal
trafﬁcking; 4) elucidation of the roles of metals in cell
regulation, signal transduction, and cell–cell signaling;
5) identification and understanding of mRNAs and
metal-, oxygen-, and redox-responsive transcriptional
and translational regulators, and their potential as
therapeutic targets; 6) elucidation of the mechanistic
roles of essential trace elements for which metabolic
functions are not yet clearly established; 7) analytical
tools that accurately monitor biologically important
pools, storage pools, and the chemical speciation of
metals; 8) biomarkers of exposure and mechanisms of
metal toxicity; 9) biomarkers for variable susceptibility
to metal toxicity in the human population; and 10)
chelation chemistry that can serve as the foundation
for therapies to ameliorate aberrant metal accumula-
tions and the effects of toxic exposures.
Interactions of Metal Complexes with Living
Systems. The therapeutic application of metal com-
plexes is an underdeveloped area of research. Basic
principles to guide the development of metallophar-
maceuticals are lacking. Metal-containing agents may
offer unique therapeutic opportunities. However, sig-
niﬁcant obstacles, including potential metal accumu-
lations and toxicities, require further research before
the promise of medicinal inorganic chemistry can be
realized.
Metal complexes may be useful as research probes
of biological function, as intermediary lead com-
pounds in the development of non–metal-containing
therapeutics, and as potential diagnostic and therapeu-
tic agents. Opportunities exist to exploit the unique
properties of metal complexes, (e.g., hydrolytic and
redox activity, Lewis acidity, electrophilicity, valency,
geometry, magnetic, spectroscopic, radiochemical
properties) to measure and/or alter cellular functions.
The actions of these compounds may provide insights
that are different from those that can be achieved
through other chemical, biochemical, or genetic
manipulations. Similarly, the actions of metal com-
plexes in whole living organisms are expected to differ
in general from the actions of non–metal-containing
agents and may offer unique research, diagnostic, or
therapeutic opportunities. Principles are needed for the
design of safe metal-containing therapeutics. 
Another goal of this program is to utilize the
power of inorganic chemistry to provide new knowl-
edge of and new approaches for intervention in bio-
logical systems. Still another goal is to improve
understanding of the reactions of metal complexes in
living systems to improve the specificity of these
interactions and gain control over the potential toxic-
ity of synthetic metal complexes. The long-term goal
is to establish the basic principles of an inorganic
medicinal chemistry that will allow for rational
design and screening of potential metallopharmaceu-
ticals in the future. 
Areas of interest include 1) reactions of metal
complexes with cellular constituents (e.g., DNA,
RNA, proteins, lipids, carbohydrates, redox substrates,
signaling molecules); 2) reactions of metal complexes
within the cellular milieu and in vivo; 3) uptake of
metal complexes into cells and delivery to speciﬁc cel-
lular compartments; 4) interactions of metal com-
plexes with specific enzymes and receptors; 5)
mechanisms by which synthetic metal complexes
recruit cell cycle, signal transduction, and other meta-
bolic pathways to alter cell functions; and 6) struc-
ture–activity relationships for ligand design to control
metal complex activity and stability in vitro and in
vivo.
The NIH Metals in Medicine meeting report
includes a list of specific research opportunities and
challenges. This list is intended to be illustrative, not
exhaustive. Investigator-initiated ideas are welcome on
any subject that will contribute to the objectives listed
in this PA.
Research encouraged by this announcement may
utilize any appropriate experimental organisms or
model systems. For some problems, interesting dis-
coveries may be found in microorganisms from
unusual environments and atypical experimental
organisms. For other problems, yeast, common inver-
tebrate and vertebrate model organisms, and human
cell/tissue cultures may be appropriate. Investigators
considering human clinical trials are strongly encour-
aged to contact the program staff.
This funding opportunity will use the regular
research (R01), exploratory research (R21), and
program project (P01) award mechanisms. For a
description of the R21 grant mechanism see
http://grants.nih.gov/grants/funding/r21.htm. For
descriptions of the P01 grant mechanism see
http://www.nigms.nih.gov/funding/grntmech.
html#b (NIGMS) and http://www.niehs.nih.gov/
dert/programs/p01.htm (NIEHS).
This funding opportunity uses just-in-time con-
cepts. It also uses the modular as well as the nonmod-
ular budget formats (see http://grants.nih.gov/grants/
funding/modular/modular.htm). Specifically, if you
are submitting an application with direct costs in each
year of $250,000 or less, use the modular budget for-
mat described in the PHS 398 application instruc-
tions, available at http://grants1.nih.gov/grants/
funding/phs398/phs398.html in an interactive for-
mat. Otherwise, follow the instructions for nonmodu-
lar research grant applications. For further assistance,
contact GrantsInfo at 301-435-0714 (telecommuni-
cations for the hearing impaired: TTY 301-451-0088)
or by e-mail: GrantsInfo@nih.gov. 
Applications must be prepared using the PHS
398 application instructions and forms (rev. 5/2001).
Applications must have a Dun & Bradstreet (D&B)
Data Universal Numbering System number as the
universal identiﬁer when applying for federal grants or
cooperative agreements. This number can be obtained
by calling 1-866-705-5711 or online at http://www.
dnb.com/us/. The D&B number should be entered
on line 11 of the face page of the PHS 398 form.
Applications must be submitted on or before the
receipt date described at http://grants.nih.gov/grants/
funding/submissionschedule.htm. The complete ver-
sion of this PA is available at http://grants.nih.gov/
grants/guide/pa-ﬁles/PA-05-001.html.
Contact: Peter C. Preusch, Division of Pharma-
cology, Physiology, and Biological Chemistry,
NIGMS, Bldg 45, Rm 2AS.43C, MSC 6200,
Bethesda, MD 20892-6200 USA, 301-594-5938, fax:
301-480-2802, e-mail: preuschp@nigms.nih.gov;
Claudia Thompson, NIEHS, DERT/OPD/CEMBB,
MD EC-21, PO Box 12233, Research Triangle Park,
NC 27709 USA, 919-541-4638, fax: 919-541-4606,
e-mail: thompso1@niehs.nih.gov; Becky Costello,
ODS, NIH, Bldg 31, Rm 1B25, MSC 2086,
Bethesda, MD 20892-2086 USA, 301-435-2920, fax:
301-480-1845, e-mail: costellb@od.nih.gov.
Reference: PA No. PA-05-001
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